Solutions for PharmacoGenetic Testing

AB Consulting for Healthcare- 4541 N.64th St., Scottsdale, AZ 85251 (480)399-2877 abenson54@msn.com

The benefits of PGx America, bringing an

additional “Best Practices” Solution to your practice, are multifaceted. Because PGxA has a

“billing guru” on staff, who settles in with your billers, they find everything there is to

legitimately find and realize a significant enhancement to a practices' regular fee

slip/patient. Even if you are leaving as little as $25/$35/patient, and in most instances out

of the Medicaid arena is $75/patient in enhancements. The additional benefits to your

practice, from a dollar standpoint is one discussion, the other points are when we look to

the three real reasons to administer PGx tests to your patients; The Medicine,The Money &

The Marketing. If we stipulate that $25/$35 per patient with over 200/300 tests being

performed per month is not motivating enough, then we are left with the best reason to

fully utilize genetic testing, the Medicine.

Your population is mostly, if not completely, medication dependent with high cross co-

morbidities of pain and depression. Those patients who are hyper-metabolizing certain

meds, including codeine, are very likely to be labeled as “drug abusers,” when in fact, they

are not realizing the necessary relief in order to live a stable, satisfying life. Those who are

very low metabolizers are also at a greater risk of adverse drug reactions, including

death. The availability of this test, at “No Cost” to the patient, makes it a necessity to be

included with the full treatment of your entire patient panel. Incoming outcomes mandates

and legal liabilities also need to be considered.

We feel confident we can bring more revenue to the clinic, but never want to lose

perspective on why we do what we do. Please take a look at the link below for additional

findings: http://www.pgxam.com/pgx-across-america.html

CONCLUSIONS:

Adoption of PharmacoGenetic tests in routine clinical practice has been sparse. One major barrier to

clinical implementation is the lack of clear, curated, peer-reviewed PharmacoGenetic guidelines. CPIC

guidelines represent a critical step enabling the translation of clinical genetic test results into actionable

prescribing decisions. All CPIC guidelines adhere to a standard format and contain the necessary

information to help clinicians translate patient-specific diplotypes for each gene into clinical phenotypes

or drug prescribing groups.

Our experiences indicate that key factors for successful development and adoption of these guidelines

include: (1) adhering to standard systems for grading levels of evidence and for assigning strength to

each prescribing recommendation; (2) close collaboration among clinicians, scientists, pharmacologists,

and informatics experts; (3) provision of clear and specific recommendations for prescribing and (4)

converting the guidelines into machine readable formats for incorporation into electronic medical

records and linking to clinical decision support tools. The underlying principle, that CPIC guidelines

provide recommendations on how to use but not whether to order genetic tests, has allowed the

guideline development process to focus on practical aspects of implementing pharmacogenomics into

clinical care. Let PGx America do a free analysis of your practice today!